5190 Neil Road
Reno, NV 89502
(address is that of the Registered Agent in Nevada - Corporate Service Center)
- Phone: 1-775-636-6548
- Fax: 1-662-510-0131
- E-mail: firstname.lastname@example.org
Mike Burke, 702-966-2473
500 Million to 6 Billion - June 08, 2009
6 Billion to 8 Billion - February 04, 2010
8 Billion to 15 Billion - February 26, 2010
Some reports are that the company no longer is a licensee for the Computer Mice and Game Controller products.
The Company offers two broad categories of products for sale:
Ergonomic Computer Mice
Cyberhand's V Series are among the most powerful in the industry. A unique feature of the Ergonomic Computer Mouse is its ability to eliminate computer related respective stress injuries such as carpal tunnel syndrome. The Cyberhand mouse is ergonomically designed to reduce stress and structurally designed to fit in a hand and respond to every hand movement. This powerful, unique ergonomic computer mouse resists all five of the major carpal tunnel disorders in the industry.
Computer Game Controllers
Cyberhand's X Series Controller is the fastest, most intelligent and most comfortable first person shooter controller on the market. The Computer Game Controllers integrate hand movement which in turn permits a variety of control functions to be performed by a single left or right handed operation resulting in a significant increase in response times over competing products. In the gaming world, where split second timing and agility determine the winners and losers, the Company's game controllers place users at the top of any game as they are 40% more responsive than competitor products. It has the ergonomic protection to completely protect the user from the effects of carpal tunnel syndrome or other RSI's while playing for extended period.
ChromoCure claims to develop and provide proprietary cancer detection systems.
The Company claims to own its technology and provide its systems on a revenue sharing basis.
The Company claims it systems measure the unique genomic characteristic common to all cancers.
The Company has provided NO proof to any of its claims.